Brian Park, PharmD, Author at Infectious Disease Advisor

Brian Park, PharmD

All articles by Brian Park, PharmD

Adeno-Associated Virus 9 Gene Therapy Granted Fast Track Status for CLN1 Disease

The Food and Drug Administration has granted Fast Track designation to ABO-202 (Abeona Therapeutics Inc), a one-time adeno-associated virus 9 (AAV9) gene therapy for the treatment of CLN1 disease, also known as infantile neuronal ceroid lipofuscinosis or infantile Batten disease. CLN1 disease is a rapidly-progressing rare lysosomal storage disease caused by a defect in the…

Next post in Antibiotics, Antimicrobial Resistance